Benzinga | Apr 29, 2021 01:24PM EDT

Abiomed Earlier Issued FY22 Guidance; Sees Sales $990M-$1.03B vs $998.13M Est.

FISCAL YEAR 2022 OUTLOOK

The company anticipates fiscal year 2022 global revenue to be in the range of $990 million to $1,030 million, representing 17% to 22% growth compared to fiscal year 2021 The company is also giving its fiscal year 2022 guidance for GAAP operating margin to be in the range of 24% to 26%. The company plans to give another formal forecast for the fiscal year on our next earnings call.